Blue Latitude Health’s consultancy is based on a rich vein of expert knowledge. Here you’ll find thought-provoking commentary, articles, and downloadable resources created by our consultants.
Explore our ideas and get a deeper understanding of the current and future trends in healthcare:
|2nd September 2016
Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.
|24th August 2016
In this article, Associate Consultant Louis Perdios talks about the immunotherapy drug Opdivo and the daunting challenges faced by BMS after disappointing results. However the future for Opdivo may not be as bleak as it seems.
|18th August 2016
What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment? Even more importantly, what do immunotherapies mean for patients who face diagnosis of advanced cancers? Senior Associate Consultants Frances Hendry and Zoe Bartley tackle these complex questions.
|16th August 2016
Associate Medical Copywriter Kulveer Singh explains how biofuel cells work, why they are an exciting alternative to normal battery power, and what the challenges are in implementing their use.
|8th August 2016
The last few years have seen a huge proliferation in the number of products entering the oncology space, with a lot more currently being investigated in clinical trials. Effective positioning in this situation is vital to cut through the noise, so we've outlined some key learnings from our extensive experience in this area.
|3rd August 2016
In this article, Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe and how the recent trends impact the opportunities available to healthcare marketers.
|19th July 2016
In the last 13 years, only one new drug has been approved for patients with Alzheimer's Disease. The most recently approved drug was in 2014, bringing the total number of agents approved across AD to 5. In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as look at the some of the glimmers of light at the end of the tunnel.
|13th June 2016
In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).